Anti-PIT1 hypophysitis after immune checkpoint inhibitor treatment
Tag: Cancer immunotherapy
Novel strategies to manage CAR-T cell toxicity
The immune-related adverse events associated with chimeric antigen receptor (CAR)-T cell therapy result in substantial morbidity as well as consid…
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
Immune-checkpoint inhibitors (ICIs) have transformed the treatment paradigm for advanced-stage squamous non-small-cell lung cancer (LUSC), a histol…
Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma
CD19-targeted chimeric antigen receptor (CAR) T cells have provided a breakthrough in the treatment of patients with relapsed and/or refractory lar…
Enhancing immunotherapy with tumour-responsive nanomaterials
The targeted delivery of immunotherapies to tumours using tumour-responsive nanomaterials is a promising area of cancer research with the potential…
Cross-priming in cancer immunology and immunotherapy
Cytotoxic T cell immune responses against cancer crucially depend on the ability of a subtype of professional antigen-presenting cells termed conve…